American College Of Cardiology 2006 Meeting In Brief
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stent study looks at long lesions: Johnson & Johnson/Cordis claimed victory for its Cypher stent over Boston Scientific's Taxus in the treatment of long, complex lesions, based on results of its LONG DES-II trial presented at the American College of Cardiology meeting in Atlanta on March 12. Six months after randomizing 500 patients with lesions greater than 25 mm to either Cypher or Taxus, investigators at the University of Ulsan, Seoul, Korea recorded less in-stent late loss among the Cypher group (0.05 mm +0.22 mm lumen diameter loss index for Cypher, versus 0.25 mm +0.35 mm for Taxus). Investigators also recorded 71% less in-segment restenosis for the Cypher group compared to Taxus...
You may also be interested in...
TCT In Brief
Abbott bioabsorbable stent 30-day success rate is 94%: Everolimus-eluting, bioabsorbable BVS coronary stent achieves 93.5% delivery success rate with no major adverse cardiac events or stent thrombosis at 30-day follow-up. Results of Abbott's ABSORB trial, for BVS use in single, de novo, native coronary vessels, were presented Oct. 24 at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., by principal investigator John Ormiston, MD, Auckland City Hospital, New Zealand. The stent demonstrated 7% recoil - "very similar to the recoil of a metallic stent," Ormiston said. Raimund Erbel, MD, University Duisburg-Essen, Germany, cautioned that the durability of polymer stent radial strength remains a concern because the polymers degrade over time (1"The Gray Sheet" April 10, 2006, p. 16)...
TCT In Brief
Abbott bioabsorbable stent 30-day success rate is 94%: Everolimus-eluting, bioabsorbable BVS coronary stent achieves 93.5% delivery success rate with no major adverse cardiac events or stent thrombosis at 30-day follow-up. Results of Abbott's ABSORB trial, for BVS use in single, de novo, native coronary vessels, were presented Oct. 24 at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., by principal investigator John Ormiston, MD, Auckland City Hospital, New Zealand. The stent demonstrated 7% recoil - "very similar to the recoil of a metallic stent," Ormiston said. Raimund Erbel, MD, University Duisburg-Essen, Germany, cautioned that the durability of polymer stent radial strength remains a concern because the polymers degrade over time (1"The Gray Sheet" April 10, 2006, p. 16)...
New Cypher PMA filed
Johnson & Johnson/Cordis filed for an in-stent restenosis indication for the sirolimus-eluting stent, firm announces May 11. Data from the 384-patient SISR trial showed that patients with blockage in previously implanted bare-metal stents who received Cypher stents had a lower incidence of target vessel failure than patients who underwent brachytherapy. Brachytherapy, or radiation from within the vessel, is the only FDA-approved treatment for in-stent restenosis. Competitor Boston Scientific's Taxus paclitaxel-eluting stent also showed positive results for the indication in the Taxus V clinical trial (1"The Gray Sheet" March 20, 2006, p. 6)...